BIOGYL Oral suspension Ref.[115632] Active ingredients: Methronidazole

A nitroimidazole derivative well absorbed and widely distributed in the body. It is metabolised by hepatic acid oxidation, hydroxylation and glucuronidation and excreted in urine and faeces with a T_½ of about 6-10 hours. After a 400 mg metronidazole (or equivalent) single oral dose, given either as metronidazole benzoate 6.4% suspension or metronidazole tablet to 10 healthy subjects in a cross-over study (Table 1), t_max is delayed by approximately 2 hours, C_max decreased by 45% and AUC by 20% corresponding to a decrease in relative bioavailability of 20% of the metronidazole benzoate 6.4% oral suspension compared to the tablet. No change in elimination half-life is reported. No metronidazole benzoate was found in plasma. These slight differences in the rate and extent of metronidazole absorption are due to the transformation of metronidazole benzoate to the active compound metronidazole by hydrolysation in the gastrointestinal tract.